Communicable Diseases, Imported

READING, England--( BUSINESS WIRE )--Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM ® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus. 1 The vaccination schedule consists of two vaccine doses injected by the intramuscular route 6 months to 36 months apart but can be given up to 7 years apart. 1 This launch was based on data from 20 clinical studies in 14 countries across Europe, the Middle East, Asia and the Americas, involving more than 6,200 children aged 12 months to 15 years who have received at least one dose of the vaccine in the context of a clinical trial. 2 The data show that AVAXIM Junior is effective in inducing a protective antibody response within two weeks in over 95% of individuals, and in nearly 100% before the booster dose administered six months after the first dose. 3 Rebecca Catterick, UK and Ireland Sanofi Vaccines General Manager , said: “Hepatitis A is one of the most prevalent travel-related vaccine-preventable diseases, so the availability of effective options like AVAXIM Junior will offer parents peace of mind knowing that they can help protect their children when travelling to high-risk areas.” Hepatitis A is one of the most common vaccine-preventable, viral infections worldwide Hepatitis A, caused by the hepatitis A virus, is primarily transmitted through contaminated food and water or by direct contact with an infectious person. 4 Incidence of the disease is closely related to socio-economic conditions, so it is most prevalent in developing countries with poor sanitary conditions and hygiene practices. 4,5 It is the most common form of viral hepatitis 6 and the third most common vaccine-preventable infection among travelers. 7 ENDS About AVAXIM ® 80U Paediatric AVAXIM Junior is indicated for active immunisation against infection caused by the hepatitis A virus in children aged 12 months to 15 years inclusive. It can be used for both primary and booster vaccination and should be given according to official recommendations. 1 Most commonly observed side effects include pain at the injection site, a general feeling of discomfort or being unwell (malaise), headache and abnormal crying. 1,3 Most reactions were limited to the first few days following vaccination with spontaneous recovery. 1,3 AVAXIM Junior is a ready-to-use suspension for injection containing 80 antigen units of inactivated hepatitis A virus and is available in 0.5ml unidoses of suspension in pre-filled syringes with attached needles. 1 About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY References 1 AVAXIM Junior SmPC. May 2021 2 Sanofi Pasteur. Data on file. March 2017 3 Sanofi Pasteur. Avaxim®80U Pediatric. Clinical Core Data Sheet. 195- Pediatric Hepatitis A vaccine - CCDS – version 15 –24 September 2020 4 WHO. WHO position paper on Hepatitis A vaccines – June 2012. Wkly Epidemiol Rec, 2012;87(28/29):261-76. 5 WHO. Health Emergency and Disaster Risk Management Fact Sheets. WATER, SANITATION AND Hygiene. December 2017. Available at: https://cdn.who.int/media/docs/default-source/disaster-mngmt/risk-management-wash-december2017.pdf?sfvrsn=81ddcc1a_1&download=true [Accessed January 2023]. 6 Luxemburger C, Dutta AK. Overlapping epidemiologies of hepatitis A and typhoid fever: the needs of the traveler. J Travel Med. 2005 Apr;12 Suppl 1:S12-21. 7 Steffen R, Behrens RH, Hill DR, Greenaway C, Leder K. Vaccine-preventable travel health risks: what is the evidence—what are the gaps? J Travel Med. 2015;22(1):1-12. Job Code: MAT-XU-2300110 (V1.0) Date of Preparation: April 2023

BRUSSELS, Jan 4 (Reuters) - European Union government officials recommended on Wednesday that passengers flying from China to the EU should have a negative COVID-19 test before they board, as Beijing plans to ease travel restrictions despite a wave of new COVID infections. The recommendation comes from the EU's Integrated Political Crisis Response group (IPCR), which is a body made up of officials from the EU's 27 governments, and is in line with a recommendation made earlier by the European Commission. China plans to ease travel restrictions on Jan 8, despite a wave of new infections which has left Chinese hospitals and funeral houses overwhelmed . The IPCR also recommended that all passengers on flights to and from China should wear face masks, that EU governments introduce random testing of passengers arriving from China and that they test and sequence wastewater in airports with international flights and planes arriving from China. The IPCR said that, together with the European Centre for Disease Control, the Commission's foreign affairs department and the World Health Organisation would continue to monitor the epidemiological situation in the EU and developments in China. "The Member States agree to assess the situation and review the introduced measures by mid-January 2023," the IPCR said in statement. The European Centre for Disease Control (ECDC) said last week it did not currently recommend measures on travellers from China, because the variants circulating in China were already in the European Union. The ECDC also said EU citizens had relatively high vaccination levels and the potential for imported infections was low compared to daily infections in the EU, with healthcare systems currently coping. Our Standards: The Thomson Reuters Trust Principles.

DUBLIN, Dec. 30, 2022 /PRNewswire/ -- The "Global Transdermal Drug Delivery Systems Market Size, Share & Industry Trends Analysis Report by Application, Type of Delivery System, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The Global Transdermal Drug Delivery Systems Market size is expected to reach $72.4 billion by 2028, rising at a market growth of 4.6% CAGR during the forecast period. Drugs are given via the skin at a predefined and controlled pace using a transdermal drug delivery system (TDDS). These methods are used to treat a variety of medical diseases, including those affecting the heart and neurological system. Skin patches can be used to deliver medications including nicotine (for stopping smoking), scopolamine (for travel sickness or motion sickness), lidocaine (for shingles pain), and nitro-glycerin (for angina). These devices offer a number of benefits, including a longer therapeutic impact, fewer side effects, increased bioavailability, better patient compliance, and simple drug therapy termination. The appendageal, transcellular, and intercellular pathways are the three main ways that drugs can enter the body. Market Growth Factors: Increase in Self-Administration of Long-Term Drugs Transdermal drug delivery systems have enhanced drug diffusion capabilities compared to more traditional drug administration methods, such as intravenous, oral, and pulmonary. The growing preference for pain-free medicine delivery among patients and clinicians is an important factor in the wide use of TDDS. The TDDS application is being boosted by the increased accessibility for self-administration of medications for illnesses that require long-term therapy, such as diabetic patients. Presence of Numerous Transdermal Products in Clinical Trial Phases There are numerous active clinical trials for transdermal products that have received FDA approval currently. These trials span from Phase I through IV investigations, and the majority use transdermal devices that have previously received FDA approval for substances including fentanyl, nicotine, and hormone treatments. These studies focus on a wide range of illness states, and many are looking at new applications for already-available transdermal products or other pharmacological combinations. Marketing Restraining Factor: Skin Layers Posing as A Barrier in Achieving Maximum Efficiency Most transdermal drugs do not achieve their full potential because of the built-in skin barrier. The function of the skin, which has multiple layers and is the body's outermost organ, is to protect it from the outside world by shielding it from poisons, heat, and chemicals. Each layer of such skin has components that obstruct transdermal delivery, including the epidermis, which serves as a barrier, and the dermis, which houses blood vessels and generates skin cells. The permeability issue of drugs through the skin would hamper the expansion of the transdermal drug delivery systems market. Application Outlook On the basis of application, the transdermal drug delivery systems market is divided into analgesics, hormone replacement therapy, hypertension, motion sickness, smoking cessation, and others. The hormone replacement therapies segment recorded a substantial revenue share in the transdermal drug delivery system market in 2021. One of their prominent use is in the menopausal symptom's treatment. Type of Delivery System Outlook Based on type of delivery system, the transdermal drug delivery systems market is bifurcated into passive and active. The hormone replacement therapies segment recorded a substantial revenue share in the transdermal drug delivery system market in 2021. One of their prominent use is in the menopausal symptom's treatment. Regional Outlook Based on region, the transdermal drug delivery system is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North American region witnessed the maximum revenue share in the transdermal drug delivery systems market in 2021. Patent expirations, which lead to new businesses joining the market, are a primary driver of growth in this region. Additionally, it is believed that significant investments made by established as well as recent market entrants, the reformulation of operating drug compounds, the repositioning of previously unsuccessful drugs, and these other factors play a significant role in the sizeable share that this region has managed to capture. Scope of the Study Market Segments Covered in the Report: By Application Analgesics Hormone Replacement Therapies Hypertension Motion Sickness Smoking Cessation Others By Type of Delivery System Passive Active By Geography North America US Canada Mexico Rest of North America Europe Germany UK France Russia Spain Italy Rest of Europe Asia Pacific China Japan India South Korea Singapore Malaysia Rest of Asia Pacific LAMEA Brazil Argentina UAE Saudi Arabia South Africa Nigeria Rest of LAMEA Key Market Players List of Companies Profiled in the Report: Viatris Inc. Bayer AG Boehringer Ingelheim GmbH Endo International plc GlaxoSmithKline plc Johnson & Johnson Novartis AG Purdue Pharma L.P. Altaris Hisamitsu Pharmaceutical Co. Inc. Key Topics Covered: Chapter 1. Market Scope & Methodology Chapter 2. Market Overview Chapter 3. Global Transdermal Drug Delivery Systems Market by Application Chapter 4. Global Transdermal Drug Delivery Systems Market by Type of Delivery System Chapter 5. Global Transdermal Drug Delivery Systems Market by Region Chapter 6. Company Profiles Companies Mentioned Viatris Inc. Bayer AG Boehringer Ingelheim GmbH Endo International plc GlaxoSmithKline plc Johnson & Johnson Novartis AG Purdue Pharma L.P. Altaris Hisamitsu Pharmaceutical Co. Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets